Seoul, Korea - Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities will present a technical session on Global Trial Solutions for Biotechs at BIOPLUS-INTERPHEX KOREA 2023 for biotechs planning regional or global trials.
Novotech’s Vice President, Global Head of Clinical Services Yooni Kim will open the session which will be followed by presentations from senior Novotech experts.
• “Pre-Clinical requirements for successful clinical trial entry” – presented by Dr. Babaji Yadav, Associate Director and Principal Toxicologist, Novotech Drug Development Consulting
• “Successful global clinical trial solutions for biotechs” – presented by HyunKyoung Kim, Project Director, Novotech
Then a panel discussion will follow lead by Yooni Kim and featuring biotech leaders and Novotech sector specialists.
Technical Session by Novotech
Time: 3:10pm (Korea)
Date: 12 July, 2023
Book a meeting with the Novotech team here or attend the Technical Session.
The conference which is co-hosted by Korea Biotechnology Industry Organization and Reed Exhibition Korea (RX Korea), and supported The Ministry of Trade, Industry and Energy is expected to attract more than 10,000 participants, 250 pharmaceutical and biotech companies, 400 exhibitors and features more than 20 conference sessions.
Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Novotech has been awarded a range of significant industry awards including a CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2022 award, and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed more than 45 Leading Site Partnership agreements over the last 3 years.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO Award, 2024 Clinical Trials Arena Award for Excellence in Business Expansion, Marketing, and Innovation, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com